CNBC March 14, 2024
Key Points
– The Food and Drug Administration approved Rezdiffra as the first-ever treatment for a common and potentially deadly liver disease that affects millions worldwide.
– The FDA’s decision means Madrigal Pharmaceuticals has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
– Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH.
The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide.
The FDA’s decision means Madrigal Pharmaceuticals has succeeded in a disease area that several...
Today's Sponsors
Today's Sponsor